title: [Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
abstract: BACKGROUND
  Previous data suggest the high incidence of gastroesophageal reflux (GER) in asthmatics, although the relationship between GER and the respiratory condition in asthmatics remain unclear. We investigated the incidence of GER in asthmatics and the association between the effects of proton-pump inhibitor (PPI) on respiratory functions and esophageal pH in asthmatics with GER.
  
  
  METHODS
  Two hundreds ninety outpatients who attended our unit with asthma received GER symptoms questionnaire used at Mayo Clinic. Twenty three of them who answered to have any GER symptom were treated with PPI (lansoprazole 30 mg/day) for eight weeks, and investigated changes in the GER symptoms and peak expiratory flow rates (PEFR) before and after treatment. Furthermore, in six of twenty three, airway hyperresponsiveness to methacholine and esophageal pH monitor for 24 hours were measured in order to evaluate the association between esophageal pH and the effect of PPI on GER during the test. Furthermore, the serum level of theophylline was analyzed for assessment of the PPI effect on theophylline metabolism.
  
  
  RESULTS
  150 of 290 asthmatics had answered to have any GER symptom including cough. Most of GER symptoms had improved except for cough after treatment with PPI. The airway hyperresponsiveness significantly improved after treatment with PPI (n=6, p<0.03), although PEF and FEV1 were not significantly changed.
  
  
  CONCLUSIONS
  These results suggest that PPI may be an effective drug for asthmatics with GER through suppression of airway hyperresponsiveness.
authors.affiliation: The Third Department of Internal Medicine, Iwate Medical University School of Medicine. atsuko-s@ace.ocn.ne.jp
authors.forename: Atsuko
authors.initials: A
authors.lastname: Sato
authors.forename: Yukio
authors.initials: Y
authors.lastname: Tanifuji
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inoue
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications*; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D012130:Respiratory Hypersensitivity / Q000188:drug therapy; D011795:Surveys and Questionnaires
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole